Publications

5674 Results

Cumulative Incidence of Financial Hardship in Metastatic Colorectal Cancer (mCRC) Patients (pts): Primary Endpoint Results for SWOG S1417CD

Authors
V Shankaran;J Unger;A Darke;J Suga;J Wade;P Kourlas;S Chandana;M O'Rourke;S Satti;D Liggett;D Hershman;S Ramsey
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 7010); American Society of Clinical Oncology 2020 Annual Meeting, poster discussion
Year
2020
Research Committee(s)
Cancer Care Delivery
Study Number(s)
S1417CD

S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma

Authors
S Patel;M Othus;J Moon;M Tetzlaff;E Buchbinder;V Sondak;M Lowe;D Campos;E Sharon;L Korde;W Carson;A Ribas;K Grossmann
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr TPS10090); American Society of Clinical Oncology 2020 Annual Meeting, TIPS poster
Year
2020
Research Committee(s)
Melanoma
Study Number(s)
S1801

An Intergroup Collaboration for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826

Authors
S Castellino;M LeBlanc;A Herrera;S Parsons;S Punnett;D Hodgson;S Rutherford;N Kahn;L Constine;K Davidson;A Prica;JW Friedberg;K Kelly
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr TPS8067); American Society of Clinical Oncology 2020 Annual Meeting, TIPS poster
Year
2020
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Residual circulating tumor DNA (ctDNA) after two months of therapy predicts progression-free and overall survival in patients treated on SWOG S1403 with afatinib +/- cetuximab

Authors
P Mack;M Redman;J Moon;S Goldberg;RS Herbst;M Melnick;Z Walther;F Hirsch;K Politi;K Kelly;D Gandara
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 9532); American Society of Clinical Oncology 2020 Annual Meeting, poster
Year
2020
Research Committee(s)
Lung
Study Number(s)
S1403

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: SWOG S1605 (NCT #02844816)

Authors
P Black;C Tangen;P Singh;D McConkey;MS Lucia;W Lowrance;V Koshkin;K Stratton;T Bivalacqua;W Kassouf;S Porten;R Bangs;M Plets;S Lerner;I Thompson
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 5022); American Society of Clinical Oncology 2020 Annual Meeting, poster discussion
Year
2020
Research Committee(s)
Genitourinary
Study Number(s)
S1605

Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: a Secondary Analysis of SWOG S0816

Authors
CS Ha;M Leblanc;H Schoder;C Pinnix;E Brem;N Bartlett;AM Evens;ED Hsi;L Rimsza;JP Leonard;BS Kahl;H Li;SM Smith;LS Constine;JW Friedberg
Journal / Conference
Leukemia & Lymphoma Oct;61(10):2442-2447
Year
2020
Research Committee(s)
Lymphoma
PMID
PMID32452714
Study Number(s)
S0816

Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel

Authors
PN Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M Van Loan;M Hussain;S Gupta;J Zhang;P Twardowski;D Quinn;N Vogelzang;I Thompson
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 5523); American Society of Clinical Oncology 2020 Annual Meeting, poster
Year
2020
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase 3 randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide

Authors
A Goldkorn;C Tangen;M Plets;G Morrison;A Cunha;T Xu;J Pinski;S Ingles;T Triche;G MacVicar;A Crispino;D McConkey;PN Lara;M Hussain;D Quinn;N Vogelzang;I Thompson;N Agarwal
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 5506); American Society of Clinical Oncology 2020 Annual Meeting, oral
Year
2020
Research Committee(s)
Genitourinary
Study Number(s)
S1216

Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702

Authors
J Meyerhardt;Q Shi;C Fuchs;D Niedzwiecki;T Zemla;P Kumthekar;K Guthrie;F Couture;JP Kuebler;J Bendell;P Kumar;D Lewis;B Tan;M Bertagnolli;A Grothey;H Hochster;R Goldberg;A Venook;CD Blanke;AF Shields
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 4003);American Society of Clinical Oncology Annual Meeting (5/29/2020 - 6/2/2020, Chicago, IL), oral
Year
2020
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Association of Prior immune anti-PD-1 antibody therapy with longer progression free survival in patients treated with intermittent versus continuous dabrafenib and trametinib: a post-hoc analysis of S1320

Authors
A Algazi;M Othus;A Daud;J Mehnert;T-G Truong;R Conry;K Kendra;GC Doolittle;JI Clark;M Messino;DF Moore;C Lao;B Faller;R Govindarajan;A Harker-Murray;L Dreisbach;J Moon;K Grossmann;R Lo;A Ribas
Journal / Conference
J Clin Oncol 38: 2020 (suppl; abstr 10039); American Society of Clinical Oncology Annual Meeting (5/29/2020 - 6/2/2020, Chicago, IL), poster
Year
2020
Research Committee(s)
Melanoma
Study Number(s)
S1320